MedTrace Logo

Primary Prevention of Hypertension in Obese Adolescents

NCT00288158 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-09-14

No results posted yet for this study

Summary

The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease. The specific aims are:

1. Test the hypothesis that lowering uric acid will improve endothelial function.
2. Test the hypothesis that lowering uric acid will reduce plasma renin activity and serum angiotensin II levels.
3. Test the hypothesis that lowering uric acid will reduce markers of inflammation

Conditions

  • Obesity
  • Pre-Hypertension
  • Hyperuricemia

Interventions

DRUG

Allopurinol

DRUG

Probenecid

DRUG

Placebo

Sponsors & Collaborators

  • Baylor University

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    lead NIH

Principal Investigators

  • Daniel I Feig, MD, PhD · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-01-31
Completion
2011-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00288158 on ClinicalTrials.gov